Experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have penned a New England Journal of Medicine perspective recognizing the United States President's Emergency Plan for AIDS Relief (PEPFAR) for 15 years of implementing an innovative program to prevent, treat, and care for persons living with HIV and AIDS. The authors stress that continued support for the U.S. State Department program is necessary to ensure an effective global response to the HIV pandemic and to set a precedent for addressing other infectious diseases worldwide.
PEPFAR has demonstrated remarkable success providing HIV services in regions of the world hardest hit by the pandemic, especially in eastern and southern Africa. Between its launch in 2003 and September 2017, PEPFAR-funded programs delivered antiretroviral therapy to more than 13.3 million men, women and children; voluntary medical male circumcision to reduce the risk of HIV acquisition to more than 15.2 million men; prenatal care that led to the prevention of 2.2 million perinatal HIV infections; and support for more than 6.4 million orphans and other vulnerable children impacted by HIV. The authors report the U.S. investment in PEPFAR also yields profound indirect benefits by fostering a humanitarian reputation for the United States abroad and better preparing health systems in developing countries to respond to disease outbreaks.
In the commentary, the authors recount the circumstances in which PEPFAR was conceived more than 15 years ago. Research supported by the NIH and others had led to the development of antiretroviral drugs and treatment regimens that increased life expectancies among people diagnosed with HIV from years to decades, and drastically reduced AIDS deaths in resource-rich nations. However, millions of people in resource-limited nations continued to die without access to adequate therapy. Seeing an opportunity to reduce suffering, President George W. Bush established a program to share the benefits of these scientific breakthroughs and other HIV services to prevent infections and treat people in 14 nations with high rates of HIV infection and AIDS deaths. Today, the program has expanded to more than 50 countries and has been instrumental in putting many communities on track for epidemic control and ultimately, ending the HIV pandemic.
AS Fauci et al. PEPFAR--15 years and counting the lives saved. New England Journal of Medicine DOI: 10.1056/NEJMp1714773 (2018).
NIAID Director Anthony S. Fauci, M.D., co-author of the perspective, is available for comment.
To schedule interviews, please contact Judith Lavelle, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®